Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome

J Pediatr Adolesc Gynecol. 1997 Aug;10(3):147-51. doi: 10.1016/s1083-3188(97)70075-5.

Abstract

Objective: The aim of this study was to evaluate the possibility of persistence of autonomous ovarian activity in girls with McCune-Albright syndrome (MAS) after withdrawal of medroxyprogesterone therapy administered for precocious puberty.

Design, setting, and participants: Five girls with MAS were followed-up 1.2 to 8.5 years after the end of treatment. The girls underwent luteinizing hormone-releasing hormone (LH-RH) tests, estradiol (E2) basal measurement, and pelvic ultrasound two times in the follow-up period.

Results: Menses resumed in four of five girls, 1.4 +/- 0.9 years after the end of treatment, at chronologic age of 11.3 +/- 1.3 years. Cycles for all girls were irregular. Three patients presented inadequate E2 levels (from 56 to 320 pg/mL) associated with low or absent gonadotropin response to LH-RH tests. The pelvic ultrasound showed ovarian cysts at the time of the study.

Conclusion: These hormonal and ultrasonographic findings provide evidence of persistence of autonomous ovarian activity in some young women with MAS.

MeSH terms

  • Child
  • Estradiol / blood
  • Female
  • Fibrous Dysplasia, Polyostotic / blood
  • Fibrous Dysplasia, Polyostotic / complications
  • Fibrous Dysplasia, Polyostotic / physiopathology*
  • Follicle Stimulating Hormone / blood
  • Follow-Up Studies
  • Humans
  • Luteinizing Hormone / blood
  • Medroxyprogesterone / therapeutic use*
  • Ovary / diagnostic imaging
  • Ovary / physiopathology*
  • Progesterone Congeners / therapeutic use*
  • Puberty, Precocious / blood
  • Puberty, Precocious / complications
  • Puberty, Precocious / drug therapy*
  • Puberty, Precocious / physiopathology*
  • Ultrasonography

Substances

  • Progesterone Congeners
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Medroxyprogesterone